<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>
Transcriptional coactivator CBP upregulates hTERT expression and tumor growth and predicts poor prognosis in human lung cancers

Transcriptional coactivator CBP upregulates hTERT expression and tumor growth and predicts poor prognosis in human lung cancers
Upregulated expression and activation of human telomerase reverse transcriptase (hTERT) is a hallmarker of lung tumorigenesis. However, the mechanism underlying the aberrant hTERT activity in lung cancer cells remains poorly understood. In this study, we found the transcriptional co-activator CBP as a new hTERT promoter-binding protein that regulated hTERT expression and tumor growth in lung adenocarcinoma cells using a biotin-streptavidin-bead pulldown technique. Chromatin immunoprecipitation assay verified the immortalized cell and tumor cell-specific binding of CBP on hTERT promoter. Overexpression of exogenous CBP upregulated the expression of the hTERT promoter-driven luciferase and endogenous hTERT protein in lung cancer cells. Conversely, inhibition of CBP by CBP-specific siRNA or its chemical inhibitor repressed the expression of hTERT promoter-driven luciferase and endogenous hTERT protein as well as telomerase activity. Moreover, inhibition of CBP expression or activity also significantly reduced the proliferation of lung cancer cells in vitro and tumor growth in an xenograft mouse model in vivo. Immunohistochemical analysis of tissue microarrays of lung cancers revealed a positive correlation between CBP and hTERT. Importantly, the patients with high CBP and hTERT expression had a significantly shorter overall survival. Furthermore, CBP was found to interact with and acetylate transactivator Sp1 in lung cancer cells. Inhibition of CBP by CBP-specific siRNA or its chemical inhibitor significantly inhibited Sp1 acetylation and its binding to the hTERT promoter. Collectively, our results indicate that CBP contributes to the upregulation of hTERT expression and tumor growth, and overexpression of CBP predicts poor prognosis in human lung cancers.
- Sun Yat-sen University China (People's Republic of)
- State Key Laboratory of Oncology in South China China (People's Republic of)
- The University of Texas Health Science Center at San Antonio United States
- Dalian Medical University China (People's Republic of)
- The University of Texas Health Science Center at Houston United States
Lung Neoplasms, Cell Survival, Sp1 Transcription Factor, Mice, Nude, Acetylation, Adenocarcinoma of Lung, Adenocarcinoma, Prognosis, CREB-Binding Protein, Gene Expression Regulation, Neoplastic, Mice, Cell Line, Tumor, Animals, Humans, RNA Interference, RNA, Small Interfering, Promoter Regions, Genetic, Neoplasm Transplantation, Cell Proliferation, Protein Binding
Lung Neoplasms, Cell Survival, Sp1 Transcription Factor, Mice, Nude, Acetylation, Adenocarcinoma of Lung, Adenocarcinoma, Prognosis, CREB-Binding Protein, Gene Expression Regulation, Neoplastic, Mice, Cell Line, Tumor, Animals, Humans, RNA Interference, RNA, Small Interfering, Promoter Regions, Genetic, Neoplasm Transplantation, Cell Proliferation, Protein Binding
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).20 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 10% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%